{
    "nctId": "NCT00053898",
    "briefTitle": "Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy",
    "officialTitle": "A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3104,
    "primaryOutcomeMeasure": "Percentage of Patients Free From Breast Cancer",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed ductal carcinoma in situ (DCIS) of the breast\n\n  * Mixed DCIS and lobular carcinoma in situ (LCIS) allowed\n* Must have undergone lumpectomy\n\n  * Margins must be histologically free of disease\n  * Re-excision to obtain tumor-free margins allowed\n  * No more than 84 days since prior lumpectomy or re-excision\n* More than 1 area of DCIS allowed provided all disease is removed with tumor-free margins\n\n  * Masses or clusters of calcification that are clinically or mammographically suspicious must be biopsied\n* No prior invasive breast cancer or DCIS\n\n  * Patients with a history of LCIS are eligible\n* No prior or concurrent invasive (including microinvasive) breast cancer\n\n  * DCIS \"suspicious\" for microinvasion allowed\n* No bilateral malignancy\n\n  * No mass or mammographic abnormality suspicious for malignancy in the opposite breast unless not malignant as proven by biopsy\n* No Paget's disease of the nipple\n* No positive ipsilateral axillary or intramammary nodes\n\n  * No palpable nodes in the ipsilateral or contralateral axilla or palpable supraclavicular or infraclavicular nodes unless not involved with tumor as proven by biopsy\n* Hormone receptor status:\n\n  * Estrogen- or progesterone-receptor positive as determined by immunohistochemistry\n\n    * Borderline results are considered positive\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* See Menopausal status\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Postmenopausal as defined by at least 1 of the following:\n\n  * Prior documented bilateral oophorectomy\n  * At least 12 months without spontaneous bleeding\n  * Age 55 or over with prior hysterectomy without oophorectomy\n  * Age 54 or under with prior hysterectomy without oophorectomy with a documented follicle-stimulating hormone level in the postmenopausal range\n\nPerformance status\n\n* Zubrod 0-2\n\nLife expectancy\n\n* At least 10 years (excluding diagnosis of breast cancer)\n\nHematopoietic\n\n* WBC normal\n\nHepatic\n\n* AST normal\n* Bilirubin normal\n* Alkaline phosphatase normal\n* No hepatic disease that would preclude administration of study drugs\n\nRenal\n\n* Creatinine normal\n* No renal disease that would preclude administration of study drugs\n\nCardiovascular\n\n* No prior documented cerebral vascular accident or transient ischemic attack\n* No prior deep vein thrombosis\n* No cardiovascular disease that would preclude administration of study drugs\n* No uncontrolled hypertension (i.e., systolic blood pressure at least 180 mm Hg or diastolic blood pressure at least 110 mm Hg based on the average of 2 or more readings at each of 2 or more visits after initial screening)\n* No uncontrolled atrial fibrillation\n\nPulmonary\n\n* No pulmonary embolus\n\nOther\n\n* Not pregnant or nursing\n* Patients with a history of non-breast malignancies are eligible provided they have been disease-free for \u2265 5 years and are deemed by their physician to be at low risk for recurrence\n* No other malignancy within the past 5 years except treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the colon, or melanoma in situ\n* No psychiatric or addictive disorders that would preclude informed consent\n* No uncontrolled diabetes, defined as hemoglobin A1C greater than 9% (fasting glucose 200 mg/dL)\n* No nonmalignant systemic disease that would preclude administration of study drugs\n\nPRIOR CONCURRENT THERAPY:\n\nEndocrine therapy\n\n* No prior or concurrent aromatase inhibitors (e.g., exemestane or letrozole) or tamoxifen\n* No concurrent raloxifene or other selective estrogen receptor modulators\n* No concurrent sex hormone therapy (e.g., estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone releasing hormone analogs, prolactin inhibitors, or antiandrogens)\n\n  * Low-dose estrogen vaginal creams or Estring allowed\n\nRadiotherapy\n\n* Radiotherapy for this cancer initiated before study is allowed\n\nSurgery\n\n* See Disease Characteristics\n* No prior or concurrent mastectomy for DCIS\n* Prior sentinel node biopsy or axillary node dissection allowed provided nodes are pathologically negative\n\nOther\n\n* No concurrent warfarin\n* No other systemic therapy for this cancer initiated before study\n* No other concurrent anticancer therapy unless permitted by the protocol investigator\n* No concurrent participation in another clinical trial of therapy for DCIS\n\n  * Concurrent participation in protocol NSABP-B-39 allowed",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}